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COVID-19 vaccine trials should seek worthwhile efficacy
Three issues are crucial in planning COVID­19 vaccine 
trials: (1) whether to demand not only proof of some 
vaccine efficacy but also proof of worthwhile efficacy; 
(2) whether the initial trials of vaccine against placebo 
should prioritise not only single­vaccine trials but also 
a multivaccine trial; and (3) whether to assess safety, 
protection against severe disease, and duration of 
protection by continuing blinded follow­up of the 
vaccine and placebo groups after definite evidence 
of short­term efficacy has emerged, but before an 
effective vaccine has been deployed locally in the general 
population.
The world needs efficient, speedy, and reliable evalu­
ation of many candidate vaccines against COVID­19. 
There is a danger that political and economic pres­
sures for rapid introduction of a COVID­19 vaccine 
could lead to widespread deployment of a vaccine 
that is in reality only weakly effective (eg, reducing 
COVID­19 incidence by only 10–20%), perhaps 
because of a misleadingly promising result from 
an underpowered trial. Deploy ment of a weakly 
effective vaccine could actually worsen the COVID­19 
pandemic if authorities wrongly assume it causes a 
substantial reduction in risk, or if vaccinated indi­
viduals wrongly believe they are immune, hence 
reducing implementation of, or compliance with, 
other COVID­19 control measures. Deployment of 
a marginally effective vaccine could also interfere 
with the evaluation of other vaccines, as subsequent 
vaccines would then have to be compared with it 
rather than with a placebo. For a vaccine superior to 
the weakly effective vaccine, the increased sample size 
required could delay recognition of its efficacy. More 
importantly, if the weak vaccine is compared against 
an even weaker vaccine, the statistical criteria used to 
analyse non­inferiority trials could well endorse the 
even weaker vaccine as being non­inferior (so­called 
bio­creep).1
The criteria used to define a successful vaccine in the 
initial clinical trials of vaccination versus placebo should 
therefore be strict enough to protect against the risk 
of a weakly effective vaccine being deployed, especially 
since there are already many candidate vaccines against 
COVID­19 to be tested,2 providing many chances to 
overestimate efficacy. Hence, the initial trials comparing 
COVID­19 vaccines versus placebo should seek reliable 
evidence not only of some efficacy but of worthwhile 
efficacy.
WHO recommends that successful vaccines should 
show an estimated risk reduction of at least one­half,3 
with sufficient precision to conclude that the true vac­
cine efficacy is greater than 30%. This means that the 
95% CI for the trial result should exclude efficacy less 
than 30%. Current US Food and Drug Administration 
guidance includes this lower limit of 30% as a 
criterion for vaccine licensure.4 As an example of 
a result that would just satisfy these two criteria, 
an evenly randomised trial with 50 cases arising 
in those vaccinated and 100 cases arising in those 
given placebo would have a 95% CI that just excludes 
30%, but would suggest 50% short­term efficacy. A 
vaccine that has 50% efficacy could appreciably reduce 
incidence of COVID­19 in vaccinated individuals, and 
might provide useful herd immunity. Hence, although 
efficacy far greater than 50% would be better, efficacy 
of about 50% would represent substantial progress.
In comparison with individual trials for each of the 
many different vaccines, a global multivaccine trial 
with a shared control group could provide more rapid 
and reliable results. Additionally, its continuous use 
of established clinical trial infrastructure could save 
time and effort, accelerating the needed discovery of 
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several safe and effective vaccines. High enrolment rates 
facilitated by flexible trial design and hundreds of study 
sites in high­incidence locations could yield results on 
short­term efficacy for each vaccine within just a few 
months of including that vaccine.
Reliable evidence is also needed about longer­term 
efficacy, vaccine safety, and protection against severe 
COVID­19. Trials of sufficient size and duration are 
needed to provide this, and to determine whether 
the vaccine can make COVID­19 more hazardous 
(so­called disease enhancement).5,6 Trials that assess 
only immunological endpoints cannot provide this 
evidence, and human challenge studies in young, 
otherwise healthy, adult volunteers might not provide 
sufficient evidence of safety or efficacy in other 
populations. Assessments of safety in multivaccine trials 
can determine directly whether particular vaccines have 
adverse effects not shared by other vaccines. Evaluation 
of multiple COVID­19 vaccines with standardised 
methodology will facilitate regulatory and deployment 
decisions.7 Unless such decisions are informed by reliable 
randomised evidence, the effect on public acceptance 
of COVID­19 vaccines could adversely affect COVID­19 
control and the uptake of vaccines against other 
diseases.8
The WHO Solidarity Vaccines Trial9 (figure) aims to 
evaluate efficiently and rapidly (within 3–6 months of 
each vaccine’s introduction into the study) the efficacy 
of multiple vaccines,10 helping to ensure that weakly 
effective vaccines are not deployed. The trial seeks to 
achieve rapid, reliable results by the simplicity of the 
trial design plus real­time checks on the quality of 
the limited amount of data sought, facilitating high 
recruitment rates. A major challenge with vaccine 
trials at fixed study sites is that unexpectedly low 
attack rates can delay progress. The WHO trial will 
mitigate this by geographical diversity, recruiting in 
many high­incidence countries through fixed and 
mobile (pop­up) research sites in localities where there 
are substantial COVID­19 attack rates at the time of 
enrolment.
For a one­dose or two­dose vaccine that halves risk 
the main result on short­term efficacy should emerge 
within 3–6 months, unless definite results for a highly 
effective vaccine emerge in interim analyses. Placebo­
controlled follow­up then continues until at least 
month 12, or until an effective vaccine is deployed 
locally. This approach increases the reliability of the 
evidence on younger and older adults, duration of 
protection, efficacy against severe disease, and any 
disease enhancement.
Funders, vaccine developers, researchers, and gov­
ern ment institutions11 have signed an international 
statement of collaboration in vaccine research. Several 
of these developers and more than 250 research sites 
intend to join the WHO Solidarity Vaccines Trial in the 
Why have an international randomised controlled trial of several candidate vaccines?
Evaluates several different 
candidate vaccines 
Permits selected vaccines to
enter the trial whenever ready 
Expeditiously enrols participants at 
sites with high rates of COVID-19
Eliminates inefficiency of designing 
and conducting separate trials 
International collaboration and
countries’ commitment 
Vaccine selection for trial
assessed using a priori criteria 
All vaccines selected for trial are
eligible for testing at some sites 
Increases the likelihood of 
finding several effective vaccines 
Flexible mix of fixed sites and
mobile (pop-up) sites
Sufficient enrolment to assess
efficacy and safety of all vaccines
Adaptive design accommodates
unanticipated circumstances
Rapid accumulation of data to 
support rigorous evaluation
Each site helps assess several 
vaccines in parallel
Shared placebo group increases 
efficiency and attractiveness
If placebo can no longer be used, 
another vaccine becomes comparator
Results within 3–6 months after 
each vaccine is ready for inclusion
Fosters participation of sites with
high COVID-19 rates 
Any effective vaccines will be tested 
at many sites
Paves the way for international
deployment of effective vaccines 
Fosters international deployment 
with equity of access
Figure: Selected design features of the WHO Solidarity Vaccines Trial 
The primary outcome is laboratory­confirmed symptoms >14 days after vaccination is completed. Analyses of each vaccine after about 40, 70, and 100 primary 
outcomes occur in the placebo group will report success if they show ≤10 versus 40, ≤30 versus 70, or ≤50 versus 100 outcomes. The third analysis is reported 
regardless of its findings. In all cases placebo­controlled follow­up continues until at least month 12 (or local deployment of an effective vaccine) to assess safety, 
disease severity, and duration of protection.
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The Lancet Small Vulnerable Newborn Series: science for a 
healthy start
The Lancet 2020 Campaign1 on child and adolescent 
health is a welcome call for a renewed focus on 
children. With less than a decade remaining to achieve 
the UN Sustainable Development Goals (SDGs), the 
campaign is a timely reminder about an unfinished 
agenda, reiterating the centrality of child survival 
and wellbeing in global development. The impacts of 
the COVID­19 pandemic bring more urgency to the 
need for increased attention to children. Although 
COVID­19 is usually mild in children, health­service 
disruptions and other indirect effects of the pandemic 
response are having devastating impacts on the 
wellbeing of pregnant women, children, and other 
vulnerable individuals.2,3 There have, for example, 
been reports of declines in institutional deliveries and 
increases in stillbirths and neonatal deaths during 
the COVID­19 pandemic in some Asian and European 
populations.4,5 
Although deaths in children younger than 5 years 
have declined substantially in the past 30 years, more 
than 5 million children still die every year.6 Almost half 
of these deaths occur during the first month of life, 
which underlines how progress in reducing neonatal 
mortality has been much slower than that for older 
children.6 In some countries, especially in sub­Saharan 
Africa, there have been increases in neonatal deaths 
during the past three decades.6 Less visible, but as 
important for families and society, are an estimated 
2·6 million third­trimester stillbirths each year.7 
About 20 million babies are born each year with low 
hope of bringing forward the time when the world 
will move beyond the widespread disease, death, and 
disruption from the COVID­19 pandemic. The trial costs 
will be a fraction of the societal costs of COVID­19, and 
this global collaboration could rebut detrimental vaccine 
nihilism and vaccine nationalism.
We all participated in writing the protocol for the WHO Solidarity Vaccines Trial 
and declare no other competing interests. This Comment reflects the views of 
the authors and should not be construed to represent the views or policies of 
the US Food and Drug Administration.
© 2020. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights 
reserved.
Philip Krause, Thomas R Fleming, Ira Longini, 
*Ana Maria Henao-Restrepo, Richard Peto, for the World 
Health Organization Solidarity Vaccines Trial Expert Group†
henaorestrepoa@who.int
†Members of the World Health Organization Solidarity Vaccines Trial Expert 
Group are: Natalie E Dean (University of Florida), Betz Halloran (Fred Hutchinson 
Cancer Centre, University of Washington), Yunda Huang (Fred Hutchinson Cancer 
Centre, University of Washington), Thomas R Fleming (Fred Hutchinson 
Cancer Centre, University of Washington), Peter B Gilbert (Fred Hutchinson 
Cancer Centre, University of Washington), Victor De Gruttola (Harvard 
Chan T H School of Public Health, University of Harvard), Pierre Gsell (World 
Health Organization), Ana Maria Henao­Restrepo (World Health Organization), 
Holly E Janes (Fred Hutchinson Cancer Centre, University of Washington), 
Philip Krause (US Food and Drug Administration), Ira Longini (University of 
Florida), Martha C Nason (US National Institutes of Health), Richard Peto 
(Nuffield Department of Population Health, University of Oxford), 
Ximena Riveros (World Health Organization), and Peter Smith (London School of 
Hygiene & Tropical Medicine).
Center for Biologics Evaluation and Research, US Food and Drug Administration, 
Washington, DC, USA (PK); Fred Hutchinson Cancer Centre, University of 
Washington, Seattle, WA, USA (TRF); Department of Biostatistics, College of 
Public Health and Health Professions College of Medicine, University of Florida, 
Gainesville, FL, USA (IL); Health Emergencies Programme, World Health 
Organization, CH­1211 Geneva 27, Switzerland (AMH­R); and Nuffield 
Department of Population Health, University of Oxford, Oxford, UK (RP)
1 Fleming TR. Current issues in non­inferiority trials. Stat Med 2008; 
27: 317–32
2 WHO. Draft landscape of COVID­19 candidate vaccines, 2020. 
Aug 25, 2020. https://www.who.int/publications/m/item/draft­landscape­
of­covid­19­candidate­vaccines (accessed Aug 20, 2020).
3 WHO. WHO target product profiles for COVID­19 vaccines. April 9, 2020. 
https://www.who.int/who­documents­detail/who­target­product­
profiles­for­covid­19­vaccines (accessed Aug 20, 2020).
4 US Food and Drug Administration. Development and licensure of vaccines 
to prevent COVID­19: guidance for industry. June, 2020. https://www.fda.
gov/regulatory­information/search­fda­guidance­documents/
development­and­licensure­vaccines­prevent­covid­19 (accessed 
Aug 20, 2020).
5 Hotez PJ, Corry DB, Bottazzi ME. COVID­19 vaccine design: the Janus face of 
immune enhancement. Nat Rev Immunol 2020; 20: 347–48.
6 Graham BS. Rapid COVID­19 vaccine development. Science 2020; 
368: 945–46.
7 Dean NE, Gsell PS, Brookmeyer R, et al. Creating a framework for 
conducting randomized clinical trials during disease outbreaks. N Engl J Med 
2020; 382: 1366–69.
8 Harrison EA, Wu JW. Vaccine confidence in the time of COVID­19. 
Eur J Epidemiol 2020; 35: 325–30.
9 WHO. An international randomised trial of candidate vaccines against 
COVID­19. May, 2020. https://www.who.int/publications­detail/
an­international­randomised­trial­of­candidate­vaccines­against­covid­19 
(accessed Aug 25, 2020).
10 WHO. Criteria for COVID­19 vaccine prioritization. May 17, 2020. 
https://www.who.int/who­documents­detail/criteria­for­covid­19­
vaccine­prioritization (accessed Aug 20, 2020).
11 WHO. Public statement for collaboration on COVID­19 vaccine 
development. April, 2020. https://www.who.int/news­room/
detail/13­04­2020­public­statement­for­collaboration­on­covid­19­
vaccine­development (accessed Aug 20, 2020).
